Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04306146 · ClinicalTrials.gov registry record · Phase 1

Study of CAD-9303 in Subjects With Schizophrenia

A Phase 1 study of Schizophrenia, sponsored by Cadent Therapeutics.

Completed
Registry status
Phase 1
Development phase
103
Enrollment target
2
Study locations

NCT04306146 is a Phase 1 study of Schizophrenia that has completed, run by Cadent Therapeutics. The registered enrollment target is 103 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (53% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04306146, a Phase 1 study of Schizophrenia, has completed, sponsored by Cadent Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
103 participants
Enrollment target
2
Study locations

Study Summary

This study will consist of Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts that will be randomized, double-blind, and placebo-controlled to assess the safety, tolerability, and pharmacokinetics of CAD-9303. The first SAD cohort will be in healthy volunteer subjects. The remaining cohorts will be in participants with schizophrenia.

Conditions Studied

Schizophrenia

Interventions

  • DRUG Placebos
  • DRUG CAD-9303

Study Locations (2)

California

  • Collaborative Neuroscience Research - Long Beach

New Jersey

  • Hassman Research Institute - Marlton

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2020-02-28
Est. Completion 2021-11-24
Phase Phase 1

Sponsor

Cadent Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04306146

The ClinicalTrials.gov registry entry for NCT04306146 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (53% lower). The listed sponsor is Cadent Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebos is the first listed.

NCT04306146 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New Jersey.

Frequently Asked Questions

What is clinical trial NCT04306146 about?

NCT04306146 is a clinical study titled "Study of CAD-9303 in Subjects With Schizophrenia". This study will consist of Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts that will be randomized, double-blind, and placebo-controlled to assess the safety, tolerability, and pharmacokinetics of CAD-9303. The first SAD cohort will be in healthy volunteer subjects. The remaini...

What is the current status of trial NCT04306146?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2020-02-28. Estimated completion is 2021-11-24.

What conditions does trial NCT04306146 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT04306146?

The interventions under investigation include: Placebos (DRUG), CAD-9303 (DRUG).

Who is sponsoring clinical trial NCT04306146?

This trial is sponsored by Cadent Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04306146 being conducted?

This trial has 2 study locations across California, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.